Bradford S. Waddell, M.D. Becomes First Surgeon In Connecticut to Implement HIPALIGN®, Handheld Sensor-based Navigation for DA Total Hip Surgery

Stamford, CT, June 26, 2018 (GLOBE NEWSWIRE) — Dr. Brad Waddell is the first surgeon in Connecticut to offer HipAlign® for direct-anterior total hip replacement. HipAlign is a sensor-based navigation technology that helps surgeons perform precise and accurate hip replacement surgeries. The HipAlign system allows Dr. Waddell to offer his patients one of the most advanced surgical technologies available in Connecticut.

The HipAlign technology acts as a GPS for surgeons, using micro-electromechanical sensors like accelerometers and gyroscopes to guide hip replacement surgery, to ensure accuracy and alignment. All of this happens in a phone-like device that sits in the surgeon’s hands, and on their surgical instruments.

“Using HipAlign technology allows for accurate placement of the hip prosthesis by using patient’s individual pelvic anatomy,” said Dr. Waddell, Orthopedic Surgeon at Hospital for Special Surgery. “Cost-effective navigation and smart instrumentation like HipAlign is the future of technology in orthopedic surgery. It’s important in that the technology allows me to combine my clinical experience and decision making along with real-time data about my patient. The resulting precision may lead to improved outcomes for my patients.” Dr. Waddell works with OrthAlign in a personal capacity.

The HipAlign technology (manufactured by OrthAlign, Inc. a California-based company) launched in 2018, building on the legacy of KneeAlign®, a technology that has powered more than 75,000 surgeries to date.

To learn more about the HipAlign surgical procedure, visit www.orthalign.com. 

ORTHALIGN, INC.

OrthAlign is a privately held medical device and technology company, developing advanced technologies that deliver healthier and more pain-free lifestyles to joint replacement patients, globally. We provide healthcare professionals with cutting edge, computer-assisted surgical tools that seamlessly and cost-effectively deliver vital data and clinical results to optimize outcomes for our patients. For more information regarding OrthAlign, please visit www.orthalign.com or contact Adam Simone (asimone@orthalign.com).

Attachment

Adam Simone
OrthAlign
asimone@orthalign.com

Innovasis Provides Business Update

SALT LAKE CITY, June 26, 2018 – Innovasis provided a business update related to recent organizational milestones.

Leadership Team Expansion

Innovasis is pleased to announce the recent expansion of their leadership team. Mike Wheelock was hired as Vice President of Sales and David Oka as Director of Business Development and Clinical Affairs.

“The addition of experienced industry veterans like David and Mike ensures Innovasis continues developing world-class distribution and supports our commitment to collect compelling clinical evidence for our evolving HA PEEK enhanced interbody platform,” said Innovasis President Mike English. “We are excited and honored to have them join our rapidly expanding team.”

Headquarters Groundbreaking

With continued company growth, Innovasis is excited to announce the groundbreaking of new headquarters in Salt Lake City, Utah. The 50,000 sq. ft. facility will include a two-station cadaver lab, in house manufacturing, and corporate offices.

“This move will allow us to train our surgeon and distribution partners in an extraordinary setting, expand our manufacturing capabilities, and create operational efficiencies crucial to remain competitive in this market,” commented English.

36th Humanitarian Trip Completed

Innovasis completed their 36th humanitarian trip to Lima, Peru. This is the second humanitarian trip the company has completed in 2018. “Our humanitarian mission the past six years includes a total of total of 60 surgeon participants and over 200 spine and cranial cases completed. We are grateful for the expert staff, surgeons, and nurses that make it possible for Innovasis to continue improving patient healthcare in Peru,” said English.

About Innovasis

Innovasis is a groundbreaking company engaged in the research, development, manufacturing, and marketing of spinal implant devices and related products. Innovasis offers a spinal product line with implants and instruments that address the major pathologies and focus areas of traditional spinal surgery.

Orthofix Realigns Business Unit Structure, Names Brad Niemann President of Global Orthofix Spine and Davide Bianchi President of Global Orthofix Extremities

June 25, 2018

LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix International N.V., (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced the realignment of its strategic business units and the promotion of Brad Niemann to President of Global Orthofix Spine, which includes the BioStim, Spine Fixation, Spinal Kinetics and Biologics businesses. The Extremity Fixation business, which will now be referred to as “Orthofix Extremities” will continue to be led globally by Davide Bianchi as the President of Global Orthofix Extremities. This alignment structures Orthofix around two pillars: Spine and Extremities.

“In 2013, Orthofix segmented its business into four strategic business units to gain better strategic and management focus and drive needed performance improvements,” said Orthofix President and Chief Executive Officer, Brad Mason. “This strategy has proved very successful over the last several years and resulted in each business performing well with solid leadership, execution and growth.

“Today we are announcing these organizational changes as part of an overall strategy to position the Company for growth acceleration and to realize opportunities that can only be achieved by leveraging our full portfolio of spine solutions,” Mason continued. “As we expand our product offerings and integrate new technologies, such as the M6® disc, we believe the time is right to further optimize our structure to better serve our surgeon customers through a two-pillar approach of a consolidated Spine group and a focused Extremities business. We are fortunate to have two extremely talented executives to lead these organizations.”

“I am excited to have the opportunity to lead the Spine group and look forward to working more closely with the current management teams from all the spine product areas,” said Brad Niemann, President of Global Orthofix Spine. “This structure will foster better collaboration and alignment by bringing these teams together under one umbrella to help ensure we make the most of our many opportunities in the market.”

Orthofix will continue to report its financial performance according to the current four strategic business unit structure until completion of this transition, which is expected to be at the beginning of 2019. Subsequently, the Company will evaluate what changes in the Company’s segment financial reporting, if any, may be required as a result of this transition. In any event, the Company will continue to provide revenue transparency into the extremities, stimulation, spine hardware, biologics and Spinal Kinetics product groups.

About Brad Niemann

Niemann joined Orthofix in 2012 as Senior Vice President, Commercial Operations and was quickly promoted to President of the BioStim strategic business unit in June 2013 where he has successfully led the efforts to expand the utilization of bone growth stimulation technology. Prior to Orthofix, he worked in a variety of management and leadership roles of increasing responsibility at DJO Global, Inc. including serving as Senior Vice President, Recovery Sciences where he led their commercial efforts. As President of Global Orthofix Spine, he will work with the leaders of the Orthofix spine businesses in the development of strategies and initiatives to advance the Company’s worldwide spine business.

About Orthofix

Orthofix International N.V. is a global medical device company focused on musculoskeletal products and therapies. The Company’s mission is to improve patients’ lives by providing superior reconstruction and regenerative musculoskeletal solutions to physicians worldwide. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedic extremities products are distributed in over seventy countries via the Company’s sales representatives and distributors. For more information, please visit www.orthofix.com.

Contacts

Orthofix International N.V.
Investor Relations
Mark Quick, 214-937-2924
markquick@orthofix.com
or
Media Relations
Denise Landry, 214-937-2529
deniselandry@orthofix.com

Peer Reviewed Results: Conformis Patient Specific iTotal CR Achieves Better Rotational Alignment and Tibial Fit Compared to Off-the-Shelf Implants

BILLERICA, Mass., June 25, 2018 (GLOBE NEWSWIRE) — Conformis Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell patient specific joint replacement implants designed to fit each patient’s unique anatomy, today announced publication of a study showing that patients treated with the iTotal CR Knee Replacement Systems achieved better tibial fit and tibial rotational alignment compared to patients treated with three different off-the-shelf (OTS) total knee arthroscopy (TKA) products. Results of the study titled “In Vivo Tibial Fit and Rotational Analysis of a Customized, Patient-Specific TKA versus Off-the-Shelf TKA” were presented in the May 2018 issue of The Journal of Knee Surgery, a leading peer-reviewed orthopedic journal.

The study, which was conducted jointly by Greg Martin, MD in Boynton Beach, Florida and Lennart Schroeder, MD candidate Julius-Maximilians-Universitaet Wuerzburg, Germany, intraoperatively compared component fit in four tibial zones. The Conformis iTotal CR implant system and three OTS cruciate retaining TKA products including Biomet Vanguard, Zimmer NexGen and DePuy Sigma were evaluated intraoperatively in a total of 44 knees. Each implant system was evaluated intraoperatively on the same 44 knees to compare each brand’s optimal tibial fit. Component rotation was then evaluated post operation using CT-based imaging converted into computer aided design (CAD) models. Using these models, simulated surgery was performed with the OTS TKAs.

“One of the compromises and decisions we surgeons often need to make intraoperatively is the best method to achieve an optimal “fit” for the patient while maintaining proper rotational alignment,” says board certified, fellowship trained hip and knee surgeon, Gregory Martin, MD. “The real benefit that I’ve found using Conformis implants is that this compromise is completely obviated. The implants fit precisely as designed with the in-built rotation, and enough relief to allow me to fine tune my rotation based on the specific patient’s anatomy. This is borne out in our results.”

The surgeon placed all implants with proper rotational alignment and the results of this study show: 37% of OTS knees showed >3mm under-coverage compared to 18% of Conformis iTotal and 18% of OTS had an overhang of >3mm compared to 0% for iTotal. In previous studies1, component overhang of greater than 3mm was linked to significantly higher post-operative pain. Additionally, when the same 44 knees were positioned for optimal fit, 45% of OTS knees had rotational errors of >5 degrees and 4% had >10 degrees. Excessive internal tibial component rotation has been found to be one of the leading factors of residual pain in TKR and can be a source of functional deficit2. No rotational deviation was observed with the Conformis iTotal implants, which are pre-aligned rotationally to match the patient’s unique anatomy.

“This is the first study to evaluate both the fit of the tibial tray and rotation of our patient-specific designed implants compared with off-the-shelf implants,” said Mark Augusti, chief executive officer and president of Conformis. “We often hear from surgeons that when they use off-the-shelf implants they need to compromise either on fit or rotation in the operating room. The results of this new study demonstrate that the Conformis iTotal CR can help surgeons address both issues at the same time. This study adds to the growing body of evidence that the Conformis iTotal CR can lead to better outcomes for patients.”

 

READ THE REST HERE

 

Exactech Earns Research Award at International Computer-Assisted Surgery Conference for ExactechGPS® Knee Application

June 20, 2018

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, a leading developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, earned the Second Place Best Clinical Podium Presentation Award for one of five new research studies presented on the company’s latest computer guidance technology for knee surgery at the International Society for Computer Assisted Orthopaedic Surgery (CAOS) annual meeting in Beijing, China earlier this month.

The award-winning research demonstrated the potential for ExactechGPS to accurately manage soft tissue balance, bone cuts and overall alignment of the knee in joint replacement surgery.

According to Orthopaedic Surgeon David Liu, MD, of The Gold Coast Centre for Bone & Joint Surgery in Queensland, Australia, “It was an honour to present several studies based on ExactechGPS and to receive this award, along with my co-authors Yifei Dai and Guillaume Bras of Exactech. This scientific meeting is unique in its focus on the role of navigation in orthopaedic surgery. I am confident that this technology plays a major role in the outcomes of joint arthroplasty.”

The five ExactechGPS studies presented at CAOS 2018 add to the more than 20 presented so far this year, including one that was recognized as the 2018 Orthopaedic Research Society’s Best Implant Poster Award. For more information on Exactech’s solutions for knee replacement and its ExactechGPS technology, visit www.exac.com.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.

Contacts

Exactech
Media Contact:
Priscilla Bennett, 352-377-1140
VP of Marketing and Corporate Communications, Exactech
media@exac.com

Zavation Medical Products Announces Brian K. Hutchison as Newest Member of its Board of Directors

JACKSON, Miss.June 20, 2018 /PRNewswire/ — Zavation Medical Products (“Zavation” or “the Company”), a LongueVue Capital Partners (“LVC”) portfolio company that designs and manufacturers high-quality spinal implants, instruments, and biologics, announced today that Brian K. Hutchison has joined its Board of Directors.

Zavation Chairman and LVC Managing Partner Rick Rees stated, “My colleagues and I are excited to welcome Brian to the Zavation family. His extensive relationships and leadership experience building orthopedic and spine businesses, first at Stryker and then as CEO of RTI Surgical, will be an invaluable resource to our team. Ultimately, his relationships are a testament to his character, which makes him a great addition to the Board of Directors. We look forward to benefiting from his accomplished career within the orthopedics and spine industry.”

“Brian has been in our shoes before and will serve as a valuable strategic resource as Zavation continues to grow,” said Jeffrey Johnson, Founder and CEO of Zavation. “But, more importantly, Brian is a cultural fit who shares our vision and understands that our priority is providing excellent customer service and quality products.”

Hutchison added, “I am delighted to join Zavation, a high growth and innovative spine company with a full-bag of products. I’ve admired Jeffrey and his team for many years, as they’ve managed remarkable growth without sacrificing customer service. I look forward to supplementing the team to further accelerate the Company’s growth trajectory.”

Hutchison brings 30 years of healthcare industry experience with him to Zavation. Most recently, Hutchison retired after serving 15 years as the Chief Executive Officer of RTI Surgical, Inc. (NASDAQ: RTIX). At RTI Surgical, he grew annual revenue from $55 million to $300 million, positioning the company as a leader in advanced biologic products. As CEO, Hutchison successfully merged RTI Surgical with Tutogen Medical in 2013 and subsequently acquired Pioneer Surgical Technologies. From 2014 to 2016, RTI Surgical was recognized as one of the fastest-growing spine companies in the world, with nearly 20% quarter-over-quarter growth.

Before RTI Surgical, Hutchison held various positions at Stryker Corporation, including serving as President of its Medical Division and Vice President of Worldwide Product Development and Distribution.

Hutchison currently serves on the Board of Directors of the University of Florida Research Foundation. He received a BBA with a focus in Accounting from Grand Valley State University in 1981 and attended Harvard Business School’s Program for Management Development in 1995.

ABOUT ZAVATION MEDICAL PRODUCTS

Based in Jackson, MS, Zavation designs, engineers, and manufactures a portfolio of spinal hardware covering key areas including thoracolumbar, cervical, interbody fusion, minimally invasive surgery, and vertebral compression fractures. Founded in 2010 with its first sale in 2012, the Company has experienced exceptional growth and created a national network of over 200 distributors across approximately 40 states. Zavation has commercialized over 12 product families since inception, with 10 additional novel products expected to launch over the next year. The Company operates a 24,000 square foot vertically integrated manufacturing facility with 70 employees.

To learn more information about Zavation and its products, visit www.zavation.com

ABOUT LONGUEVUE CAPITAL

LongueVue Capital is a private equity firm focused on making situation-driven, value-oriented investments in lower middle market companies (up to $150 million in annual revenue) to support buy-outs, recapitalizations, acquisitions, and growth. LVC currently has $425 million under management across two funds. Since its formation in 2001, LVC has made successful investments in a wide variety of industries, including healthcare, business services, transportation and logistics, energy services, and niche manufacturing. LVC is based in New Orleans with additional offices in New York and Salt Lake City. For more information, please visit www.lvcpartners.com.

SOURCE LongueVue Capital Partners

Related Links

http://www.lvcpartners.com

Kuros Biosciences to present promising clinical case studies with MagnetOs at leading spine surgery conference

Schlieren (Zurich), Switzerland, June 19, 2018

Kuros Biosciences will this week present results from several investigator-led clinical case studies of MagnetOs Granules at the 15th annual State of Spine Surgery Think Tank, a leading conference uniquely dedicated to innovation in spinal surgery.

The case studies, in which MagnetOs Granules were implanted in the spine, were performed by Alwyn Jones MB ChB, BSc, MSc, FRCS, FRSC (Orth), Consultant Orthopaedic Spinal Surgeon at Spire Cardiff Hospital in the UK.

The key clinical outcomes at six months were improved back and leg pain. The most important fusion outcomes were good incorporation of MagnetOs in the posterior fusion bed, graft resorption and remodelling to bone, and progression towards fusion.

Key takeaways from the case studies were:

  • MagnetOs Granules were well‐tolerated and no device related adverse events were reported in the small cohort of patients requiring spinal fusion
  • MagnetOs Granules were easy to apply as a stand‐alone graft or when mixed with bone marrow aspirate (BMA) or local bone
  • Resorption and remodelling of MagnetOs Granules was evident from as early as 3 months post‐implantation
  • MagnetOs Granules promoted spinal fusion in a mixed cohort of patients when implanted using 5 different surgical approaches

Alwyn Jones said: “I implanted MagnetOs in a cohort of five patients requiring spinal fusion in 2017 and I’m very pleased with their progress. In all cases, my radiographic data indicated remodelling of MagnetOs and progression towards a fusion. All five patients had a reduction in pain, improvement in disability index and improved clinical symptoms compared to their pre-surgical assessment. This initial experience has encouraged me to use MagnetOs in my broader clinical practice.”

Joost de Bruijn, Chief Executive Officer of Kuros, said: “The results from these investigator-led clinical case studies with MagnetOs are very gratifying and underline the interest of the clinical research community in our CE marked product. The MagnetOs Granules were easy to apply and showed clear clinical benefits for patients, giving them an improved quality of life with less pain.”

MagnetOs promotes local bone formation equivalent to current gold standard, autograft. MagnetOs is a bone graft substitute intended to fill bony voids or gaps of the human skeletal system and promote the formation of bone at the implanted site. A substantial number of clinically relevant and predictive studies have demonstrated its equivalence to the current gold standard (patient’s own bone, which may not be available in sufficient quantities and/or involves morbidity, costs and pain associated with its harvesting from another healthy site of the patient’s body). MagnetOs is a bone graft comprising biphasic calcium phosphate with an advanced submicron surface topography that directs bone formation after implantation. With its unique submicron surface topography, MagnetOs preferentially directs early wound healing toward the bone-forming pathway, resulting in an osteoinductive claim in Europe. MagnetOs is available as granules and as a putty formulation.

The State of Spine Surgery Think Tank, formerly known as the Cabo Meeting, takes place June 21-13 in Aruba.

For further information, please contact:

Kuros Biosciences AG
Michael Grau
Chief Financial Officer
Tel +41 44 733 47 47
michael.grau@kurosbio.com

Media & Investors
Hans Herklots
LifeSci Advisors
+41 79 598 7149
hherklots@lifesciadvisors.com

About Kuros Biosciences AG

Kuros Biosciences (SIX:KURN) is focused on the development of innovative products for bone regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. Visit www.kurosbio.com for additional information on Kuros, its people, science and product pipeline.

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

News release (pdf)

Kuros Biosciences Ltd, Wagistrasse 25, CH-8952 Schlieren

OrthoGrid Systems Announces Immediate Launch of New HipGrid® NINE for Outpatient Total Hip Replacement

SALT LAKE CITYJune 18, 2018 /PRNewswire/ — OrthoGrid Systems, Inc., a leading innovator of radiographic assessment and alignment technology for orthopedics, today announced the commercial release of its new patent-protected HipGrid® NINE System for outpatient total hip replacement.  Featuring the same clinically validated technology utilized in the original HipGrid®, OrthoGrid’s HipGrid® NINE system is designed to seamlessly integrate with C-arm systems commonly found at ambulatory surgical centers and hospitals.

“Outpatient total hip replacement procedures are growing rapidly due in large part to the potential for added convenience, reduced costs, and quicker return to home for the patient,” explained Edouard Saget, President of OrthoGrid Systems.  “Increasingly, our customers have demanded to have a HipGrid® that is compatible with 9-Inch C-arm systems commonly found in outpatient surgery centers, and so we are pleased to immediately commence shipments of this compelling new product.”

Designed with an innovative BOA® Fit Attachment System and high contrast markings, the HipGrid® NINE is controlled intra-operatively by the physician, integrates into the standard surgical workflow with no disposables or instrumentation, and can be fully utilized in conjunction with implant systems from all vendors.

Orthopedic surgeon Erik Kubiak, MD, noted that, “as the healthcare system moves away from unconstrained spending and physicians and hospitals work together to deliver higher-quality care for a reasonable cost, OrthoGrid’s HipGrid® NINE hits the mark by enabling excellent clinical value at an attractive economic price.  I will continue relying on OrthoGrid technologies for my total hip replacement patients.”

The HipGrid® NINE System is available for sale in the USA through OrthoGrid’s sales & service team.  Please visit our website at www.orthogrid.com to learn more about our company and how to schedule a free product trial of any OrthoGrid Systems technology.

About OrthoGrid Systems, Inc.
OrthoGrid Systems is a rapidly expanding global leader in intra-operative radiographic assessment and alignment technologies for orthopedics, with specialized applications available or in development for hip arthroplasty, trauma, knee replacement, and other common procedures performed over 1 million times per year in aggregate in the USA and 3 million times globally.  OrthoGrid helps to overcome the limitations of traditional low resolution, distorted imaging technology by revealing inherent image distortion, enhancing intra-operative decision making for physicians performing orthopedic procedures.  Learn more about OrthoGrid and our products by visiting our website at www.orthogrid.com.

Media Contact: Mark Carrico. Director of Marketing
Email: 197221@email4pr.com
Phone: 801-703-5866

SOURCE OrthoGrid Systems

Related Links

https://orthogrid.com

EOS imaging Launches New EOSone Private Practice Program

June 15, 2018

PARIS–(BUSINESS WIRE)–EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI – Eligible PEA – PME), the pioneer of 2D/3D imaging and data solutions for orthopedics, today announced the launch of EOSone, its new Private Practice Program, at Becker’s 16th Annual Future of Spine + The Spine, Orthopedic and Pain Management-Driven ASC Conference, being held June 14-16 in Chicago.

The EOSone program is designed to address the unique needs of private practices and to ensure that safe imaging is available to all patients, not just those treated in a traditional hospital environment. The program includes support to assist sites with patient communication and education about low dose, 3D imaging, and patient specific surgical planning with respect to their conditions and treatment plans.

“In the U.S., the private practice sector accounts for 73 percent of all orthopedic practices*, representing a significant opportunity for the EOS technology,” said Marie Meynadier, Chief Executive Officer of EOS imaging. “We launched the EOSone program as an option for private clinics to better inform patients interested in safe and personalized orthopedic care about our EOS platform, 3D models, and surgical planning solutions. We also include in this program customized financing options to facilitate access for private practices to our comprehensive platform.”

Because private practices are often hindered by the initial/upfront investment associated with capital equipment, the EOSone program offers sites various options to match the sites’ estimated volumes, with access to the full suite of EOS products, including 3D services, 3D surgical planning solutions, and system services, training, support, and updates for the duration of the program.

*Becker’s Spine: 11 Statistics and Facts About Orthopedics and Orthopedic Practices

About EOS imaging
EOS imaging designs, develops and markets EOS®, a major innovative medical imaging solution dedicated to osteoarticular pathologies and orthopedics combining equipment and services and targeting a $2B per year market opportunity. EOS imaging is currently present in 31 countries, including the United States under FDA agreement, Japan, China and the European Union under CE labelling, through the over 250 installed EOS® platforms representing around one million patient exams every year. Revenues were €37.1M in 2017, e.g. a +32% CAGR over 2012-2017.

For more information, please visit www.eos-imaging.com.

EOS imaging has been selected to integrate the EnterNext © PEA – PME 150 index, composed of 150 French, listed companies on the Euronext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Contacts

EOS imaging
Marie Meynadier
CEO
Ph: +33 (0)1 55 25 60 60
investors@eos-imaging.com
or
Press Relations (US)
Joanna Zimmerman
The Ruth Group
Ph: 646-536-7006
jzimmerman@theruthgroup.com
or
Investor Relations (US)
Matt Picciano / Emma Poalillo
The Ruth Group
Ph: 646-536-7008 / 7024
EOS-imagingIR@theruthgroup.com

Centinel Spine Announces Lumbar Total Disc Replacement coverage by TRICARE

NEW YORKJune 14, 2018 /PRNewswire/ — Centinel Spine, LLC is pleased to announce that TRICARE, the Military Health System for almost 10 million beneficiaries world-wide, has updated its coverage policy to now cover the company’s prodisc® L Anterior Lumbar Total Disc Replacement system, the most studied total disc replacement platform in the world.  More patients globally now have access to this market leading technology, a potential alternative to spinal fusion that is designed to relieve pain, maintain spinal motion and reduce post-operative recuperation time. The TRICARE extended coverage has far-reaching impact as it applies to both active duty and retired military personnel.  “With years of total disc replacement experience, I have witnessed extreme patient recovery with this technology.  This extended coverage policy will provide more patients with access to a proven surgery that offers better mobility and faster return to an active lifestyle,” stated spine surgeon Robert Masson, M.D. (Masson Spine Institute, Orlando FL).

The coverage policy was changed in a communication published on May 8, 2018, and made effective retroactively to November 16, 2017. The bulk of the TRICARE beneficiaries are Active Duty Service Members and their family members, along with retired service members.

TRICARE has supported cervical total disc replacement for many years, but this is the first time that it has extended coverage to lumbar total disc replacement.  “I look forward to extending the access to this technology in the lumbar spine – I have had significant experience with enabling military personnel to rapidly return to active duty, and appreciate the opportunity to provide lumbar total disc replacements to other TRICARE beneficiaries,” stated spine surgeon John F. Hall, M.D. (Flagstaff Bone & Joint, Flagstaff, AZ).

prodisc L has the longest use of any lumbar total disc replacement system in the U.S. (FDA approval in 2006), and has received coverage by numerous insurance providers since FDA approval. The prodisc technology platform has been the subject of over 400 articles, which have reported on over 13,000 patients’ lives.

“The TRICARE approval is the latest in a continuing trend of positive coverage decisions by carriers, and we welcome TRICARE beneficiaries to the pool of patients that are able to benefit from this life-changing treatment option.  More patients will now have access to the most proven technology in the world, with global clinical usage of almost thirty years,” stated John Viscogliosi, CEO of Centinel Spine.

About Centinel Spine

Centinel Spine, LLC is the largest privately-held spine company, focused on anterior column reconstruction. For more information on Centinel Spine products and technologies, please visit the Company’s web site at www.CentinelSpine.com.

The company began operations in August 2008, through the merger-acquisition of two pioneering medical device companies: Raymedica, LLC and Surgicraft, LTD. Today, Centinel Spine still embraces the pioneering culture developed at both originating companies, and continues its corporate mission of becoming the leading anterior column support spine franchise, providing elegantly simple implants and instruments that are tissue-sparing and generate superior clinical outcomes.

Centinel Spine derived its name from the “Sentinel Sign”, the radiographic confirmation of a successful fusion anterior to the interbody device.

For more information, please contact:

Varun Gandhi
SVP, Corporate Finance & Strategic Planning

Centinel Spine, LLC
900 Airport Road, Suite 3B
West Chester, PA 19380
Phone: 484-887-8871
Email: v.gandhi@centinelspine.com

Wendy F. DiCicco
Chief Operating and Chief Financial Officer

Centinel Spine, LLC
900 Airport Road, Suite 3B
West Chester, PA 19380
Phone: 484-887-8837
Email: w.dicicco@centinelspine.com

SOURCE Centinel Spine, LLC

Related Links

http://www.centinelspine.com